Skip to Accessibility Tools Skip to Content Skip to Footer

Technivie (ombitasvir, paritaprevir, and ritonavir)

How is Technivie used to treat HCV

Technivie (ombitasvir, paritaprevir, and ritonavir) is a fixed-dose combination medication indicated for adults with HCV genotype 4 without cirrhosis or with compensated cirrhosis.1 Technivie is also indicated for use with ribavirin. Two of Technivie’s components are direct-acting antiviral medications that act as an HCV NS5A inhibitor (ombitasvir) and an NS3/4A protease inhibitor (paritaprevir). The third component is a CYP3A inhibitor. There is a potential for hepatitis B reactivation in individuals taking Technivie who have a history of HBV. Prior to taking Technivie, your provider should test you for HBV and note any history you have with the condition. It is important to also consult the prescribing information for any medications you are also taking in combination with Technivie, including ribavirin.2

What are the ingredients in Technivie?

The active ingredients in Technivie are ombitasvir, paritaprevir, and ritonavir.

How does Technivie work?

Technivie’s first active ingredient, ombitasvir, is a direct-acting antiviral that inhibits HCV NS5A. NS5A is a nonstructural protein made by the HCV virus that is important to the virus’ growth and replication. The exact mechanism by which NS5A works is unknown. The inhibitor works to eliminate these crucial proteins made by the virus utilized for RNA replication and virion assembly. Technivie’s next active ingredient, paritaprevir, is also a direct-acting antiviral that acts as an HCV NS3/4A protease inhibitor. This protease is an essential enzyme require for viral replication. In theory, by inhibiting this enzyme the virus will be prevented from further growth and reproduction. Many direct-acting antivirals work in this manner, targeting proteins, enzymes, and specific steps in the HCV life cycle. The final active ingredient in Technivie is ritonavir, which is a CYP3A inhibitor, acting to heighten levels of paritaprevir.3

What are the possible side effects of Technivie?

Multiple clinical trials evaluated the safety and efficacy of Technivie. The most common side effects of Technivie with ribavirin for individuals without cirrhosis are weakness, tiredness, nausea, and insomnia. For those taking Technivie and ribavirin with compensated cirrhosis the most common side effects are:

  • Fatigue
  • Weakness
  • Headache
  • Musculoskeletal pain
  • Skin reactions
  • Itchiness
  • Insomnia
  • Sleep or mood disorders
  • Dizziness
  • Nausea
  • Difficulty breathing

This is not an exhaustive list of all potential side effects of Technivie. Talk to your healthcare provider or pharmacist for further information.

Things to note about Technivie

If taken with ribavirin, all precautions and risks for ribavirin should be considered. There is also a possibility of HBV reactivation while taking Technivie if you have a history of HBV. Your provider will administer a blood test before starting Technivie to monitor your risk of HBV reactivation. Reactivation of HBV could cause serious liver problems including liver failure or death.

When taking Technivie, there is also a chance of developing severe liver problems, leading to liver failure or death. Additionally, estradiol-containing medicines may increase your liver function blood test results, and these medications (which include some birth control products) should not be taken while on Technivie. Your provider will monitor your liver function before and during treatment, however, you should contact your provider right away if you notice the following liver-related symptoms:

  • Weakness
  • Loss of appetite
  • Nausea and vomiting
  • Yellowing of skin or eyes
  • Color changes in stools
  • Tiredness
  • Confusion
  • Swelling of stomach area

Before staring Technivie talk to your provider if you:

  • Have or have had hepatitis B infection
  • Have or have had liver problems other than those related to HCV
  • Have had a liver transplant
  • Have any other medical conditions, including HIV
  • Are taking any other medications, supplements, or vitamins
  • Are pregnant or are planning to become pregnant. It is not known if Technivie will affect an unborn baby.
  • Are breastfeeding or planning to breastfeed. It is not known if Technivie can pass through breast milk.

Dosing information

Technivie is a once-daily oral medication to be taken with a meal daily. A typical dose of Technivie is two tablets containing 12.5mg of ombitasvir, 75mg of paritaprevir, and 50mg of ritonavir each. Technivie is indicated for use with ribavirin. Do not start taking any medications without alerting your provider while on Technivie. Do not stop taking Technivie or change the dose of Technivie without talking to your provider. If you take too much Technivie, seek help at your local emergency room immediately.

Written by: Casey Hribar | Last reviewed: June 2019
  1. Technivie Prescribing Information. AbbVie, Inc. Mar 2017. Available from:
  2. Copegus (ribavirin) Prescribing Information. Aug 2011. Available from:
  3. Pockros, PJ. “Direct-acting antivirals for the treatment of hepatitis C virus infection.” Jan 2017. Available from: